Lilly Strategy: Timely, Valued Medicines to Patients

December 2, 2013

Pharmaceutical Executive

Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline.


Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline.

For more videos tune in to:



Related Content:

News